Health Boards
UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following glucagon-like peptide-1 (GLP-1) analogue therapy. Their findings raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions due to the direct impact on innate natural killer T (iNKT) cells.
The clinical team based in St Vincent’s University Hospital found an unexpected improvement in the severity of psoriasis in a patient with type 2 diabetes within days of starting GLP-1 analogue therapy. They surmised this was due to the direct action of GLP-1 on iNKT cells.
The team began treating two obese patients with type 2 diabetes and psoriasis with the GLP-1 analogue, liraglutide. Both patients experienced relief from their psoriasis symptoms within days of starting treatment and the psoriasis area and severity index (PASI) decreased in both.
Describing the laboratory findings, Dr. Andrew E. Hogan, UCD Newman Scholar and senior scientist said, “There was an alteration in iNKT cell number before and after commencing treatment; an increased number in the circulation and decreased number in psoriatic plaques. We also found that iNKT cells expressed GLP-1 receptor and modulated cytokine production”.
Professor Donal O’Shea believes that “Although extensive research will be required to investigate GLP-1 immune cell interactions, the potential benefit for inflammatory conditions such as psoriasis is promising”.
Source: medicalxpress.com
The clinical team based in St Vincent’s University Hospital found an unexpected improvement in the severity of psoriasis in a patient with type 2 diabetes within days of starting GLP-1 analogue therapy. They surmised this was due to the direct action of GLP-1 on iNKT cells.
The team began treating two obese patients with type 2 diabetes and psoriasis with the GLP-1 analogue, liraglutide. Both patients experienced relief from their psoriasis symptoms within days of starting treatment and the psoriasis area and severity index (PASI) decreased in both.
Describing the laboratory findings, Dr. Andrew E. Hogan, UCD Newman Scholar and senior scientist said, “There was an alteration in iNKT cell number before and after commencing treatment; an increased number in the circulation and decreased number in psoriatic plaques. We also found that iNKT cells expressed GLP-1 receptor and modulated cytokine production”.
Professor Donal O’Shea believes that “Although extensive research will be required to investigate GLP-1 immune cell interactions, the potential benefit for inflammatory conditions such as psoriasis is promising”.
Source: medicalxpress.com